

General information about company

Scrip code*	524404	
NSE Symbol*	MARKSANS	
MSEI Symbol*	NOTLISTED	
ISIN*	INE750C01026	
Name of company	MARKSANS PHARMA LIMITED	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	05-02-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	09-01-2026	
Description of presentation currency	INR	
Level of rounding	Millions	
Reporting Type	Quarterly	
Reporting Quarter	Third quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited	
Segment Reporting	Single segment	
Description of single segment	Pharmaceutical Formulation	
Start date and time of board meeting	05-02-2026 12:25	
End date and time of board meeting	05-02-2026 13:15	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	The Company has no outstanding loans and debt securities.

Financial Results - Ind-AS

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-10-2025	01-04-2025	
Date of end of reporting period	31-12-2025	31-12-2025	
Whether results are audited or unaudited	Unaudited	Unaudited	
Nature of report standalone or consolidated	Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	3397.29	9799.04
	Other income	158.58	760.57
	Total income	3555.87	10559.61
2	Expenses		
(a)	Cost of materials consumed	1510.03	4429.44
(b)	Purchases of stock-in-trade	160.19	598.03
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	61.76	7.12
(d)	Employee benefit expense	327.04	890.63
(e)	Finance costs	3.57	9.74
(f)	Depreciation, depletion and amortisation expense	88.3	254.75
(g)	Other Expenses		
1	Other Expenses	583.82	1698.06
	Total other expenses	583.82	1698.06
	Total expenses	2734.71	7887.77
3	Total profit before exceptional items and tax	821.16	2671.84
4	Exceptional items	0	0
5	Total profit before tax	821.16	2671.84
6	Tax expense		
7	Current tax	208.39	561.82
8	Deferred tax	3.65	22.27
9	Total tax expenses	212.04	584.09
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	609.12	2087.75
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	609.12	2087.75
17	Other comprehensive income net of taxes	9.34	7.83
18	Total Comprehensive Income for the period	618.46	2095.58
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		

	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	453.16	453.16	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	1.34	4.61	
	Diluted earnings (loss) per share from continuing operations	1.34	4.61	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	1.34	4.61	
	Diluted earnings (loss) per share from continuing and discontinued operations	1.34	4.61	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block

NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025.

1. The standalone unaudited financial results for the quarter and nine months ended 31 December 2025 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 05 February 2026. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion.

2. The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation.

3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'.

4. Other income (net) includes the following net foreign exchange differences including forward contracts:

Description	Quarter ended 31-Dec-25	Nine Months ended 30-Sep-25	Year Ended 31-Dec-24	Year Ended 31-Dec-25	Year Ended 31-Dec-24	Year Ended 31-Mar-25
-------------	-------------------------	-----------------------------	----------------------	----------------------	----------------------	----------------------

Net gain / (loss)	117.75	175.10	265.38	255.12	169.00	194.80
-------------------	--------	--------	--------	--------	--------	--------

5. During nine months ended 31 December 2025, the Board of Directors and Shareholders of the Company have approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 September 2025 to the eligible employees of the Company and its Subsidiary Companies.

Textual Information(4)

Other Comprehensive Income

	Date of start of reporting period	01-10-2025	01-04-2025
	Date of end of reporting period	31-12-2025	31-12-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurements of the net defined benefit liabilities/assets	12.48	10.47
	Total Amount of items that will not be reclassified to profit and loss	12.48	10.47
2	Income tax relating to items that will not be reclassified to profit or loss	3.14	2.64
3	Amount of items that will be reclassified to profit and loss		
1	Remeasurements of the net defined benefit liabilities/assets	0.00	0.00
	Total Amount of items that will be reclassified to profit and loss	0.00	0.00
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	9.34	7.83

Details of Impact of Audit Qualification

Whether results are audited or unaudited	Unaudited		
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion		
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results	Yes		
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	MSKA & Associates LLP	Yes	31-07-2027

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	18-01-2023
Amount Raised	3724
Report filed for Quarter ended	31-12-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	No deviation / variation
Comments of the Audit Committee after review	Satisfactory
Comments of the auditors, if any	No

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Expansion Programme	No	3724	0	3724	0	

Signatory Details

Name of signatory	Harshavardhan Panigrahi
Designation of person	Company Secretary and Compliance Officer
Place	Mumbai
Date	05-02-2026

